Geron (GERN) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Geron (GERN) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -0.88% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 15.19% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -0.27% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -7.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 16.85% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 96.08% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.68% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 18.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.84% |
| Mar 31, 2026 | -10.71% |
| Dec 31, 2025 | 14.40% |
| Sep 30, 2025 | 22.87% |
| Jun 30, 2025 | 1.45% |
| Mar 31, 2025 | -12.19% |
| Dec 31, 2024 | -25.62% |
| Sep 30, 2024 | -37.16% |
| Jun 30, 2024 | -44.26% |
| Mar 31, 2024 | -23.89% |
| Dec 31, 2023 | -48.06% |
| Sep 30, 2023 | -48.74% |
| Jun 30, 2023 | -33.67% |
| Mar 31, 2023 | -20.97% |
| Dec 31, 2022 | -50.28% |
| Sep 30, 2022 | -35.16% |
| Jun 30, 2022 | -48.51% |
| Mar 31, 2022 | -38.68% |
| Dec 31, 2021 | -94.56% |
| Sep 30, 2021 | -54.98% |